- Conditions
- Sarcoma, Nausea, Vomiting
- Interventions
- Palonosetron - Single Dose, Palonosetron - Triple Dose, Adriamycin, Ifosfamide chemotherapy (AI), Zinecard, Mesna, Vincristine, Dexamethasone
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 601–624
of 714
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma
- Interventions
- Epoetin Alfa, Exercise, Autologous Peripheral Blood Stem Cell Transplantation, Red Blood Cell Transfusion, Thalidomide, Heparin, Low-Molecular-Weight, Platelet Transfusion, Melphalan, Total Therapy II
- Drug · Behavioral · Biological
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- Not listed
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Sarcoma, Chemotherapy-induced Nausea and Vomiting, Effects of Chemotherapy, Adverse Effects of Medical Drugs
- Interventions
- Fosaprepitant, Dexamethasone, 5HT3 receptor antagonist, Ifosfamide-based chemotherapy (AI), Doxorubicin, Mesna, Ifosfamide, Vincristine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Langerhans Cell Histiocytosis
- Interventions
- Prednisone, Vinblastine, mercaptopurine, INDOMETHACIN, Methotrexate, Cytosine Arabinoside, 2-chlorodeoxyadenosine, hematopoietic stem cell transplantation (RIC-HSCT), Intravenous immunoglobulin
- Drug · Procedure · Biological
- Lead sponsor
- North American Consortium for Histiocytosis
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 36 more
- Conditions
- Lymphoma
- Interventions
- oblimersen sodium, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
- Biological · Drug
- Lead sponsor
- British Columbia Cancer Agency
- Other
- Eligibility
- 19 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
- Interventions
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Pegaspargase, Positron Emission Tomography, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, Vincristine Sulfate
- Procedure · Biological · Drug + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 365 Days to 25 Years
- Enrollment
- 5,951 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2032
- U.S. locations
- 203
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more
- Conditions
- Lymphoblastic Lymphoma
- Interventions
- Prednisone, Vincristine, Daunorubicin, PEG-asparaginase, Erwinia asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine, Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Hydrocortisone, Etoposide
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 2
- States / cities
- San Diego, California • Memphis, Tennessee
- Conditions
- Leukemia, Myelocytic, Acute
- Interventions
- Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 8
- States / cities
- Palo Alto, California • Boston, Massachusetts • Detroit, Michigan + 4 more
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- ME-401, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
- Drug
- Lead sponsor
- Deepa Jagadeesh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Lymphoma
- Interventions
- bevacizumab, cyclophosphamide, doxorubicin, prednisone, vincristine
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 110
- States / cities
- Greenbrae, California • Palo Alto, California • Fort Collins, Colorado + 77 more
- Conditions
- Lymphoma
- Interventions
- epratuzumab, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 162
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 102 more
- Conditions
- Multiple Myeloma
- Interventions
- Doxil®, Vincristine, Dexamethasone, Arsenic Trioxide
- Drug
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Peripheral T Cell Lymphoma
- Interventions
- Belinostat Injection, Pralatrexate Injection, CHOP, COP
- Drug
- Lead sponsor
- Acrotech Biopharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 504 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 10
- States / cities
- Clovis, California • Santa Monica, California • Aurora, Colorado + 7 more
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- acalabrutinib, placebo, Prednisone, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 611 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 32
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Irvine, California + 28 more
- Conditions
- Retinoblastoma
- Interventions
- subtenon Carboplatin, Topotecan Hydrochloride, Vincristine, Filgrastim
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Up to 10 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Rhabdomyosarcoma
- Interventions
- Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Radiation, Bevacizumab, Sorafenib, Myeloid Growth Factor, Lymph Node Sampling, Irinotecan, Ifosfamide, Etoposide, Etoposide Phosphate, Doxorubicin, Dexrazoxane, ^1^1C-methionine
- Drug · Procedure
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2030
- U.S. locations
- 4
- States / cities
- Jacksonville, Florida • Memphis, Tennessee • Fort Worth, Texas
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Iodine-131 Anti-B1 Antibody, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)
- Drug
- Lead sponsor
- Corixa Corporation
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • New York, New York • Philadelphia, Pennsylvania
- Conditions
- Lymphoma
- Interventions
- filgrastim, CHOP regimen, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2006
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Recurrent Neuroblastoma, Neuroblastoma
- Interventions
- Fenretinide/LXS Oral Powder, Ketoconazole, Vincristine
- Drug
- Lead sponsor
- South Plains Oncology Consortium
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Dallas, Texas • Fort Worth, Texas + 1 more
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia
- Interventions
- Dexamethasone, Vincristine, Daunorubicin, Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine), Methotrexate, Cytarabine
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2039
- U.S. locations
- 5
- States / cities
- San Diego, California • Baton Rouge, Louisiana • Charlotte, North Carolina + 2 more
- Conditions
- Kaposiform Hemangioendothelioma (KHE), Kasabach-Merritt Syndrome, Tufted Angioma
- Interventions
- Vincristine, Sirolimus
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- Up to 31 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 7
- States / cities
- Palo Alto, California • Atlanta, Georgia • Baltimore, Maryland + 4 more
- Conditions
- Sarcoma, Ewing, Rhabdomyosarcoma
- Interventions
- PEN-866, Vincristine, Temozolomide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years to 39 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland
- Conditions
- Lymphoma
- Interventions
- Bleomycin sulfate, Stanford V regimen, Doxorubicin hydrochloride, Etoposide, Mechlorethamine hydrochloride, Prednisone, Vinblastine, Vincristine sulfate
- Biological · Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1989 – 2015
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Leukemia
- Interventions
- filgrastim, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, therapeutic hydrocortisone, vincristine sulfate, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 18 Months to 29 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 135
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 116 more